ArticleAnti-cancer drugs2018

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.

Cynthia Bernier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.